UNSPSC 51343806: Lamivudine/zidovudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343806 Lamivudine/zidovudine is a Commodity code that in recent state and local solicitations represents emergency medical supplies, naloxone, pharmaceuticals, and over-the-counter products procured by health departments, fire departments, and state health agencies rather than the specific antiretroviral drugs the code name denotes. The mismatch between the code's nominal scope and the actual work being solicited reflects how state and local procurement systems sometimes apply generic pharmaceutical codes to broader emergency response and pharmacy benefit acquisitions. State and local governments buying under this code are sourcing naloxone kits, medical and first aid consumables for emergency response, generic pharmaceuticals through cooperative purchasing agreements, and direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions.

Recent activity shows Seminole County, Florida issuing an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the City of Tampa issuing a sealed bid (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered market set-aside for certified Small Local Business Enterprises at 5 percent discount; the Texas Health and Human Services Commission issuing an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with award effective July 1, 2026. Geographic activity spans Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon and other participating jurisdictions.